Approximately 800,000 people experience a stroke in the United States every year. Presently, there is no treatment to enhance the regeneration of the vascular system in the brains of stroke sufferers. Zhittya Genesis Medicine's management believes that several hundred thousand patients would benefit from its angiogenesis drug that would stimulate new blood vessel growth in the brain to re-establish blood perfusion to areas of the brain that were damaged by a stroke. Utilizing Zhittya Genesis Medicine's drug, there have been successful studies in animal models of stroke. Zhittya's management believes that their stroke drug would treat an unmet medical need and qualify for the breakthrough therapy designation.